Search research articles
Contact Us
Filters
Showing results (51-60 of 83) with videos related to
Page
of 9
Sort By:
European Urology
|
April 12, 2021
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer
Carissa E Chu, Mohammed Alshalalfa, Martin Sjöström, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Ivan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Cell
|
June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates
Anil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Anil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao, Shalini Chopra, Kai Trepka, et al.
Cancer Discovery
|
June 26, 2012
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression
Laurie E Littlepage, Adam S Adler, Hosein Kouros-Mehr, et al.
Frontiers in Oncology
|
March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
Divya Natesan, Li Zhang, Henry J Martell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2020
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Sinan Wang, Jun Li, Jun Hua, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 83) with videos related to
Sort By:
Page
of 9
European Urology
|
April 12, 2021
Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer
Carissa E Chu, Mohammed Alshalalfa, Martin Sjöström, et al.
Journal for Immunotherapy of Cancer
|
May 13, 2021
<i>TERT</i> promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
Ivan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
Cell
|
June 16, 2018
Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 22, 2026
Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates
Anil P Bidkar, Scott Bidlingmaier, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 13, 2025
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Anil P Bidkar, Robin Peter, Anju Wadhwa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 14, 2023
Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Anil P Bidkar, Sinan Wang, Kondapa Naidu Bobba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2022
CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Ning Zhao, Shalini Chopra, Kai Trepka, et al.
Cancer Discovery
|
June 26, 2012
The transcription factor ZNF217 is a prognostic biomarker and therapeutic target during breast cancer progression
Laurie E Littlepage, Adam S Adler, Hosein Kouros-Mehr, et al.
Frontiers in Oncology
|
March 24, 2022
APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer
Divya Natesan, Li Zhang, Henry J Martell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2020
Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET
Sinan Wang, Jun Li, Jun Hua, et al.
Page
of 9